Education
About Us
Working with TipRanks
Follow Us
LivaNova PLC (LIVN)
NASDAQ:LIVN
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.87Last Year’s EPS
0.93Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 22.81%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and successful clinical trials, positioning LivaNova well for future growth. However, challenges such as the SNIA litigation liability, limited U.S. Epilepsy revenue growth, and tariff impacts were noted. Despite these challenges, the positive aspects, including revenue growth and clinical successes, outweighed the negatives.Company Guidance
During the first quarter of 2025 earnings call, LivaNova PLC provided updated guidance, reflecting strong operational performance and strategic advancements. The company raised its organic revenue growth outlook to 7% to 8% for the full year, driven by a 10% organic revenue increase in the first quarter, with notable strength in the Cardiopulmonary segment and improved commercial execution in the Global Epilepsy business. The Cardiopulmonary segment saw a 15% revenue increase, driven by a 30% growth in heart-lung machine placements and high demand for oxygenators. The company also discussed the 12-month OSPREY trial data for treating obstructive sleep apnea, with a 65% responder rate, and addressed the $360 million liability related to the SNIA litigation. Despite potential tariff impacts, LivaNova anticipates manageable headwinds. The updated guidance also includes an adjusted diluted EPS range of $3.60 to $3.70, incorporating the SNIA impact and other operational improvements.Strong Organic Revenue Growth
LivaNova achieved 10% organic revenue growth versus the prior year, driven by the continued success of the Essenz rollout, demand for Cardiopulmonary consumables, and strong neuromodulation performance in the Europe and Rest of World regions.
Cardiopulmonary Segment Performance
Revenue for the Cardiopulmonary segment increased by 15% to $176 million in the quarter, with Heart-lung machine revenue growing approximately 30% versus the prior year period.
OSPREY Trial Success
The OSPREY trial demonstrated a 65% responder rate at 12 months for proximal hypoglossal nerve stimulation therapy, showing rapid and sustained improvement for patients with severe obstructive sleep apnea.
Positive Cash Flow and Cash Position
LivaNova's cash balance increased to $738 million, up from $429 million at year-end 2024, with adjusted free cash flow for the quarter at $20 million.
Updated 2025 Guidance
LivaNova raised its overall organic growth outlook by 100 basis points to between 7% and 8%, reflecting strong first-quarter performance and strategic execution.
LIVN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LIVN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $35.16 | $43.50 | +23.72% |
Feb 25, 2025 | $49.50 | $41.70 | -15.76% |
Oct 30, 2024 | $52.97 | $51.34 | -3.08% |
Jul 31, 2024 | $51.30 | $49.40 | -3.70% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does LivaNova PLC (LIVN) report earnings?
LivaNova PLC (LIVN) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is LivaNova PLC (LIVN) earnings time?
LivaNova PLC (LIVN) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LIVN EPS forecast?
LIVN EPS forecast for the fiscal quarter 2025 (Q2) is 0.87.